The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis
This study utilizes real data from WHO-VigiAccess, which offers valuable insights for clinical reference. On one hand, we confirm both existing and potential adverse effects associated with androgen antagonists. On the other hand, We analyzed the possible future research directions, thereby supporting the case for more scientific treatment.
Authors
- Jiangjie Chen (ORCID: https://orcid.org/0000-0002-2613-0386)
- Chiting Yuan (ORCID: https://orcid.org/0009-0008-6878-6325)
- Jianqing Wang (ORCID: https://orcid.org/0000-0001-8794-8678)
- Liwei Zhang (ORCID: https://orcid.org/0000-0002-0515-9841)
- Fangfang Wang (ORCID: https://orcid.org/0000-0002-5441-4490)
- Wei Wang (ORCID: https://orcid.org/0000-0002-1342-5302)
- Weixing Huang (ORCID: https://orcid.org/0000-0001-7861-7498)
- Jia You (ORCID: https://orcid.org/0000-0002-0942-3144)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Wenzhou Medical University (CN)
- Zhejiang Taizhou Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
- Taizhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-27
- DOI
- https://doi.org/10.3389/fphar.2025.1570661
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China